Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8C5Q

CK2 kinase bound to inhibitor AB668

Summary for 8C5Q
Entry DOI10.2210/pdb8c5q/pdb
DescriptorCasein kinase II subunit alpha, SULFATE ION, 2-methylpropyl 5-fluoranyl-3-[1-[[1-[2-[[4-(2-methylpropyl)phenyl]sulfonylamino]ethyl]piperidin-4-yl]methyl]-1,2,3-triazol-4-yl]-1~{H}-indole-2-carboxylate, ... (6 entities in total)
Functional Keywordskinase bivalent inhibitor, transferase
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight88433.44
Authors
Krimm, I.,Guichou, J.F. (deposition date: 2023-01-10, release date: 2024-01-24, Last modification date: 2025-02-05)
Primary citationBancet, A.,Frem, R.,Jeanneret, F.,Mularoni, A.,Bazelle, P.,Roelants, C.,Delcros, J.G.,Guichou, J.F.,Pillet, C.,Coste, I.,Renno, T.,Battail, C.,Cochet, C.,Lomberget, T.,Filhol, O.,Krimm, I.
Cancer selective cell death induction by a bivalent CK2 inhibitor targeting the ATP site and the allosteric alpha D pocket.
Iscience, 27:108903-108903, 2024
Cited by
PubMed Abstract: Although the involvement of protein kinase CK2 in cancer is well-documented, there is a need for selective CK2 inhibitors suitable for investigating CK2 specific roles in cancer-related biological pathways and further exploring its therapeutic potential. Here, we report the discovery of AB668, an outstanding selective inhibitor that binds CK2 through a bivalent mode, interacting both at the ATP site and an allosteric αD pocket unique to CK2. Using caspase activation assay, live-cell imaging, and transcriptomic analysis, we have compared the effects of this bivalent inhibitor to representative ATP-competitive inhibitors, CX-4945, and SGC-CK2-1. Our results show that in contrast to CX-4945 or SGC-CK2-1, AB668, by targeting the CK2 αD pocket, has a distinct mechanism of action regarding its anti-cancer activity, inducing apoptotic cell death in several cancer cell lines and stimulating distinct biological pathways in renal cell carcinoma.
PubMed: 38318383
DOI: 10.1016/j.isci.2024.108903
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.5 Å)
Structure validation

248942

PDB entries from 2026-02-11

PDB statisticsPDBj update infoContact PDBjnumon